Cargando…

The effects of Alpha-2a and Beta-1a Interferons on the Coronavirus disease 2019 prognosis

Background: The pandemic coronavirus disease 2019 (COVID-19) has been associated with substantial mortality worldwide. Efforts have continued to find an effective treatment for COVID-19. In vitro activity of interferon (IFN) subtypes has been shown against the SARS-CoV and MERS-CoV. Furthermore, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Haghbin, Ali, Ghaffari-Nazari, Haniyeh, Taghavi, Mohammad Reza, Vakili, Vida, Rastgou, Sahar, Khoshkhui, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: HBKU Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660257/
https://www.ncbi.nlm.nih.gov/pubmed/38025320
http://dx.doi.org/10.5339/qmj.2023.sqac.10
_version_ 1785148398515519488
author Haghbin, Ali
Ghaffari-Nazari, Haniyeh
Taghavi, Mohammad Reza
Vakili, Vida
Rastgou, Sahar
Khoshkhui, Maryam
author_facet Haghbin, Ali
Ghaffari-Nazari, Haniyeh
Taghavi, Mohammad Reza
Vakili, Vida
Rastgou, Sahar
Khoshkhui, Maryam
author_sort Haghbin, Ali
collection PubMed
description Background: The pandemic coronavirus disease 2019 (COVID-19) has been associated with substantial mortality worldwide. Efforts have continued to find an effective treatment for COVID-19. In vitro activity of interferon (IFN) subtypes has been shown against the SARS-CoV and MERS-CoV. Furthermore, the superiority of IFN-β over IFN-α2b and IFN-α2a has been demonstrated in MERS treatment. Early studies showed a low plasma level of IFNs in the peripheral blood or lungs of patients with severe COVID-19. This study assessed the effects of IFN-alpha-2a and -beta-1a on the prognosis of patients with covid-19 infection. Methods: We conducted a triple-blind randomized clinical trial on adult patients with moderate to severe COVID-19 from April 2021 to June 2021. The patients were diagnosed based on clinical and laboratory findings and randomly assigned into four groups (A, B, C, and D) using the envelope allocation method. Patients in group A received IFN β-1a; group B received IFN β-1a placebo; group C received IFN α-2a, and group D was treated with IFN α-2a placebo. All patients concomitantly received the national protocol medications as well. Results: A total of 95 eligible patients were randomly assigned into groups. National Early Warning Score 2 (NEWS2) index showed significant differences between groups only on the first day of admission (p-value = 0.001). CT scan scores on the first and tenth days slightly improved, although they were not statistically significant. Duration of hospitalization and hospital discharge did not significantly differ among all treated groups (Table 1). Mortality rates showed no significant statistical difference between the groups. However, viral clearance significantly accelerated in the patients receiving IFN β-1a or IFN α-2a (p < 0.05). Conclusion: It seems that IFN α-2a and IFN β-1a are ineffective in treating COVID-19 patients. Further randomized clinical trials with large sample sizes are needed to estimate the effects of IFN α-2a or IFN β-1a on the outcomes of COVID-19 disease.
format Online
Article
Text
id pubmed-10660257
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher HBKU Press
record_format MEDLINE/PubMed
spelling pubmed-106602572023-11-19 The effects of Alpha-2a and Beta-1a Interferons on the Coronavirus disease 2019 prognosis Haghbin, Ali Ghaffari-Nazari, Haniyeh Taghavi, Mohammad Reza Vakili, Vida Rastgou, Sahar Khoshkhui, Maryam Qatar Med J Second Qatar Allergy Conference Background: The pandemic coronavirus disease 2019 (COVID-19) has been associated with substantial mortality worldwide. Efforts have continued to find an effective treatment for COVID-19. In vitro activity of interferon (IFN) subtypes has been shown against the SARS-CoV and MERS-CoV. Furthermore, the superiority of IFN-β over IFN-α2b and IFN-α2a has been demonstrated in MERS treatment. Early studies showed a low plasma level of IFNs in the peripheral blood or lungs of patients with severe COVID-19. This study assessed the effects of IFN-alpha-2a and -beta-1a on the prognosis of patients with covid-19 infection. Methods: We conducted a triple-blind randomized clinical trial on adult patients with moderate to severe COVID-19 from April 2021 to June 2021. The patients were diagnosed based on clinical and laboratory findings and randomly assigned into four groups (A, B, C, and D) using the envelope allocation method. Patients in group A received IFN β-1a; group B received IFN β-1a placebo; group C received IFN α-2a, and group D was treated with IFN α-2a placebo. All patients concomitantly received the national protocol medications as well. Results: A total of 95 eligible patients were randomly assigned into groups. National Early Warning Score 2 (NEWS2) index showed significant differences between groups only on the first day of admission (p-value = 0.001). CT scan scores on the first and tenth days slightly improved, although they were not statistically significant. Duration of hospitalization and hospital discharge did not significantly differ among all treated groups (Table 1). Mortality rates showed no significant statistical difference between the groups. However, viral clearance significantly accelerated in the patients receiving IFN β-1a or IFN α-2a (p < 0.05). Conclusion: It seems that IFN α-2a and IFN β-1a are ineffective in treating COVID-19 patients. Further randomized clinical trials with large sample sizes are needed to estimate the effects of IFN α-2a or IFN β-1a on the outcomes of COVID-19 disease. HBKU Press 2023-11-19 /pmc/articles/PMC10660257/ /pubmed/38025320 http://dx.doi.org/10.5339/qmj.2023.sqac.10 Text en © 2023 Haghbin, Ghaffari-Nazari, Taghavi, Vakili, Rastgou, Khoshkhui, licensee HBKU Press. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Second Qatar Allergy Conference
Haghbin, Ali
Ghaffari-Nazari, Haniyeh
Taghavi, Mohammad Reza
Vakili, Vida
Rastgou, Sahar
Khoshkhui, Maryam
The effects of Alpha-2a and Beta-1a Interferons on the Coronavirus disease 2019 prognosis
title The effects of Alpha-2a and Beta-1a Interferons on the Coronavirus disease 2019 prognosis
title_full The effects of Alpha-2a and Beta-1a Interferons on the Coronavirus disease 2019 prognosis
title_fullStr The effects of Alpha-2a and Beta-1a Interferons on the Coronavirus disease 2019 prognosis
title_full_unstemmed The effects of Alpha-2a and Beta-1a Interferons on the Coronavirus disease 2019 prognosis
title_short The effects of Alpha-2a and Beta-1a Interferons on the Coronavirus disease 2019 prognosis
title_sort effects of alpha-2a and beta-1a interferons on the coronavirus disease 2019 prognosis
topic Second Qatar Allergy Conference
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660257/
https://www.ncbi.nlm.nih.gov/pubmed/38025320
http://dx.doi.org/10.5339/qmj.2023.sqac.10
work_keys_str_mv AT haghbinali theeffectsofalpha2aandbeta1ainterferonsonthecoronavirusdisease2019prognosis
AT ghaffarinazarihaniyeh theeffectsofalpha2aandbeta1ainterferonsonthecoronavirusdisease2019prognosis
AT taghavimohammadreza theeffectsofalpha2aandbeta1ainterferonsonthecoronavirusdisease2019prognosis
AT vakilivida theeffectsofalpha2aandbeta1ainterferonsonthecoronavirusdisease2019prognosis
AT rastgousahar theeffectsofalpha2aandbeta1ainterferonsonthecoronavirusdisease2019prognosis
AT khoshkhuimaryam theeffectsofalpha2aandbeta1ainterferonsonthecoronavirusdisease2019prognosis
AT haghbinali effectsofalpha2aandbeta1ainterferonsonthecoronavirusdisease2019prognosis
AT ghaffarinazarihaniyeh effectsofalpha2aandbeta1ainterferonsonthecoronavirusdisease2019prognosis
AT taghavimohammadreza effectsofalpha2aandbeta1ainterferonsonthecoronavirusdisease2019prognosis
AT vakilivida effectsofalpha2aandbeta1ainterferonsonthecoronavirusdisease2019prognosis
AT rastgousahar effectsofalpha2aandbeta1ainterferonsonthecoronavirusdisease2019prognosis
AT khoshkhuimaryam effectsofalpha2aandbeta1ainterferonsonthecoronavirusdisease2019prognosis